AP BIOSCIENCES INC.
Area: Pharmaceutical and Medical Devices
Booth No: L322
Website: http://www.apbioinc.com
Exhibitor Profile
AP Biosciences is specializing in bispecific development since 2013.
AP BIO has successfully licensed 2 bispecifics to Innovent and Tasly. Leveraging R&D capabilities, we develop a series of CD137-based T-cell engagers. The leading AP203 entered Phase 1 in 2023, AP402 and AP601 are on track for IND filing in 12 months.
In 2023, AP BIO was listed on the Emerging Stock Board of TWSE. We have recently secured $38M in financing. Developing safe and effective therapies is our commitment.
Exhibitors you may be interested in
Highest Rated